ResultsIQ › Latest results › Kwality Pharmaceuticals Limited
Kwality Pharmaceuticals Limited Q4 FY25 results deck summary
NSE: KPL · BSE: 539997
Results deck of 5 Jun 2025, summarised by AI from the filing.
Revenue ₹370 cr (FY24: ₹307 cr, FY23: ₹251 cr).
Key takeaways
- FY25 revenue Revenue ₹370 cr (FY24: ₹307 cr, FY23: ₹251 cr).
- Biologics progress Erythropoietin POC established Q3 FY26; clinical trials for Etanercept planned Q1 FY27.
- Regulatory risk Forward-looking statements subject to risks and uncertainties beyond the company's control.
Kwality Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q1 FY27: Earnings call (10 Aug 2026), Results deck (10 Aug 2026)
- Q4 FY26: Earnings call (19 May 2026), Results deck (19 May 2026)
- Q3 FY26: Results deck (12 Feb 2026)
- Q4 FY25: Results deck (5 Jun 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.